Related Experiment Video
Updated: Jun 25, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
MRPL12 Acts as A Novel Prognostic Biomarker Involved in Immune Cell Infiltration and Tumor Progression of Lung
Yangyang Hu1, Yue Liu1, Chenchao Ma1
1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Abstract:
Mitochondrial ribosomal protein L7/L12 (MRPL12) is a member of the mitochondrial ribosomal proteins (MRPs). However, the biological function of MRPL12 in lung adenocarcinoma (LUAD) remains unclear. The expression and prognostic value of MRPL12 in LUAD were systematically analyzed using UALCAN, TIMER, HPA, Kaplan-Meier plotter, and GEPIA databases. The relationship between MRPL12 and immune infiltrates was investigated using TIMER and TISIDB databases. The clinical significance of MRPL12 in LUAD patients was validated using a tissue microarray (TMA). Cellular functional experiments were carried out to examine the influences of MRPL12 knockdown on cell proliferation, migration, and invasion. MRPL12 was significantly upregulated in LUAD samples, and high MRPL12 expression was correlated with worse prognosis. MRPL12 expression was markedly associated with immunomodulators, chemokines, and infiltration levels of multiple immune cells. Furthermore, TMA results confirm the upregulation of MRPL12 expression in LUAD, and MRPL12 was identified as an independent prognostic factor in LUAD patients. MRPL12 knockdown inhibited proliferation, migration, and invasion of LUAD cells. These data indicate that MRPL12 is a prognostic biomarker and correlated with immune infiltrates in LUAD. Therefore, MRPL12 shows potential as a therapeutic target for LUAD.
Insights
Mitochondrial ribosomal protein L7/L12 (MRPL12) is elevated in lung adenocarcinoma (LUAD), correlating with poor prognosis and influencing immune cell infiltration. Targeting MRPL12 may offer a new therapeutic strategy for LUAD patients.
Area of Science:
- Molecular Biology
- Oncology
- Immunology
Background:
- Mitochondrial ribosomal proteins (MRPs) play crucial roles in cellular functions.
- The specific role of Mitochondrial ribosomal protein L7/L12 (MRPL12) in lung adenocarcinoma (LUAD) is not well understood.
Purpose of the Study:
- To investigate the expression, prognostic value, and biological function of MRPL12 in LUAD.
- To explore the association between MRPL12 and immune infiltrates in LUAD.
- To evaluate MRPL12 as a potential therapeutic target for LUAD.
Main Methods:
- Bioinformatic analysis using UALCAN, TIMER, HPA, Kaplan-Meier plotter, and GEPIA databases.
- Investigation of MRPL12 and immune infiltrates using TIMER and TISIDB databases.
- Validation of clinical significance via tissue microarray (TMA) and functional experiments (MRPL12 knockdown).
Main Results:
- MRPL12 was significantly upregulated in LUAD tissues compared to normal tissues.
- High MRPL12 expression was associated with unfavorable prognosis and identified as an independent prognostic factor.
- MRPL12 expression correlated with immunomodulators, chemokines, and the infiltration of various immune cells.
- MRPL12 knockdown suppressed LUAD cell proliferation, migration, and invasion.
Conclusions:
- MRPL12 serves as a potential prognostic biomarker in LUAD.
- MRPL12 expression is linked to the tumor immune microenvironment in LUAD.
- MRPL12 represents a promising therapeutic target for lung adenocarcinoma.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
